JacksonWC, ManningJS, ConnorPD, et al.Retrospective study of olanzapine in depressive and anxious states in primary care. Prim Care Companion J Clin Psychiatry, 2004; 6:199–202.
2.
MoY, YamF. Rational use of second-generation antipsychotic for the treatment of ICU delirium: A neuropharmacological approach. J Pharm Pract, 2015; pii:0897190015585763.
3.
LindbergN, WirkkunenM, TaniP, et al.Effect of a single-dose of olanzapine on sleep in healthy females and males. Int Clin Psychopharmacol, 2002; 17:177–184.
MeltzerHY, FibigerHC. Olanzapine: A new typical antipsychotic drug. Neuropsychopharmacology, 1996; 14:83–85.
6.
WashingtonNB, BrahmNC, KissackJ. Which psychotropics carry the greatest risk of QTc prolongation?. Curr Psychiatry, 2012; 11:36–39.
7.
MillerDD. Atypical antipsychotics: Sleep, sedation, and efficacy. Prim Care Companion J Clin Psychiatry, 2004; 6(Suppl 2):3–7.
8.
NasrallahH. A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology, 2003; 28Suppl 1:83–96.
9.
PrommerE. Olanzapine: Palliative medicine update. Am J Hosp Palliat Care, 2013; 30:75–82.
10.
FremauxT, ReymannJM, ChevreuilC, et al.Prescription of olanzapine in children and adolescent psychiatric patients. Encephale, 2007; 33:188–196.
11.
Product Information: ZYPREXA(R) oral tablets, olanzapine oral tablets. Lilly USA, LLC (per FDA), Indianapolis, IN, 2013.
12.
GlareP, MillerJ, NikolovaT, TickooR. Treating nausea and vomiting in palliative care: A review. Clin Interv Aging, 2011; 6:243–259.
13.
KaneishiK, KawabataM, MoritaT. Olanzapine for the relief of nausea in patients with advanced cancer and incomplete bowel obstruction. J Pain Symptom Manage, 2012; 44:604–607.
14.
PassikSD, LundbergJ, KirshKL, et al.A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manage, 2002; 23:526–532.
15.
HockingCM, KichenadasseG. Olanzapine for chemotherapy-induced nausea and vomiting: Asystematic review. Support Care Cancer, 2014; 22:1143–1151.
16.
NavariRM, NagyCK, GraySE. The use of olanzapine versus metoclopramide for the treatment of breakthrough nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer, 2013; 21:1655–1663.
17.
GrassiL, CaraceniA, MitchellA, et al.Management of delirium in palliative care: A review. Curr Psychiatry Rep, 2015; 17:550.
18.
ElsayemA, BushSH, MunsellMF, et al.Subcutaneous olanzapine for hyperactive or mixed delirium in patients with advanced cancer: A preliminary study. J Pain Symptom Manag, 2010; 40:774–782.
19.
BreitbartW, TremblayA, GibsonC. An open trial of olanzapine for the treatment of delirium in hospitalized cancer patients. Psychosomatics, 2002; 43:175–182.
20.
PollackMH, SimonNM, ZaltaAK, et al.Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: A placebo controlled study. Biol Psychiatry, 2006; 59:211–215.
21.
SharpleyAL, AttenburrowME, HafiziS, et al.Olanzapine increases slow wave sleep and sleet continuity in SSRI-resistant depressed patients. J Clin Psychiatry, 2005; 66:450–454.
22.
NavariRM, BrennerMC. Treatment of cancer-related anorexia with olanzapine and megestrol acetate: A randomized trial. Support Care Cancer, 2010; 18:951–956.
23.
NaingA, DalalS, AbdelrahimM, et al.Olanzapine for cachexia in patients with advance cancer: An exploratory study of effects on weight and metabolic cytokines. Support Care Cancer, 2015; 23:2649–2654.
24.
MontgomeryW, TreuerT, KaragianisJ, et al.Orally disintegrating olanzapine review: Effectiveness, patient preference, adherence, and other properties. Patient Prefer Adherence, 2012; 6:109–125.
